Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Bacterial Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 158639
The Regents also hereby grant to Licensee an exclusive license under The Regents property rights in The Hybridomas to make or propagate, have made, make derivatives and use The Hybridomas and all derivatives made therefrom by Licensee and to make, have made, use and sell Licensed Products, including, but not limited to, Licensed Products for both diagnostic and therapeutic purposes, throughout the world where The Regents may lawfully grant such a license.
The Regents also grant to Licensee the right to issue sublicenses.
The licensed property includes Pending U.S. patent application 781,242, entitled Monoclonal Antibody Reactive with Pseudomonas Aeruginosa and Pending U.S. patent application, serial number 855,878, entitled Monoclonal Antibodies Binding Determinants of Gram Negative Bacteria.
IPSCIO Record ID: 238995
(i) The U.S. Continuation-in-Part application entitled 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/566,853 (U.C. Case No. B96-002-2) filed on December 4, 1995, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents, that claims priority to Serial Number 08/506,666 (U.C. Case No. B96-002-1, now abandoned) filed on July 25, 1995,
(ii) The U.S.. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/646,605 (U.C. Case No. B96-002-3) filed May 8, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the and assigned to Regents and issued as U.S. Patent No. 5,811,097, that is a CIP of Serial Number 08/566,853, which is a U.S. CIP of 08/506,666,
(iii) The U.S. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/760,288 (U.C. Case No. B96-002-4) filed December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents,
(iv) PCT International Patent application, Serial Number US96/19375 filed on December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel and assigned to Regents (U.C. Case No. B93-002/PCT) that claims the convention priority benefits of U.S. Patent Application Serial No. 08/566,853 dating from the U.S. filing date of December 4, 1995, and U.S. Patent Application Serial No. 08/646,605 dating from the U.S. filing date of May 8, 1996, and
(v) All other international patents and patent applications, and/or any divisions, continuations, reissues and claims in continuations-in-part that are (a) entitled to the priority filing date of Serial Numbers 08/506,666, 08,566,853, 08/646,605 or 08/760,288 and (b) are claimed or described in Serial Numbers 08/506,666, 08/566,853, 08/646,605 or 08/760,288.
Sublicensed Products means within the Sublicensed Field of Use
(i) Any product produced using a Licensed Method, or for use in the practice of a Licensed Method,
(ii) Any method, process, material or product the manufacture, use or sale of which would be an infringement of any pending claim (were it to issue) or issued claim of the Licensed Patent Rights, or
(iii) Any material, method, process or product, or part thereof, that
(A) Is covered by a valid claim of any issued, unexpired patent within Licensed Patent Rights. A claim within the Licensed Patent Rights shall be presumed to be valid unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken, or
(B) Is covered by any claim being prosecuted in a pending application directed to the Invention (were it to issue).
Invention means the inventions described in 'Blockade of T-Lymphocyte Down-Regulation Associated with CTLA-4 Signaling' as described in Regents Case No. B96-002.
IPSCIO Record ID: 260370
The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.
— High Affinity Human Antibodies to Novel Tumor Antigens;
— Bi-specific Single Chain Fv scFv Antibody Molecule; and,
— Human Erb-B Antibodies.